Fundraising FoxMPM BioImpact — 2025 Investments
5 investments dated 2025 · listed companies and verified rows first · show all
Crossbow Therapeutics develops TCR-mimetic antibody therapies designed to target cancer antigens by mimicking T-cell receptors, with a focus on treating solid tumors and hematologic malignancies.
AI & Machine LearningBiotechMedical DevicesCambridge, US
Alexander Nolte(Executive Officer)inDmitri Wiederschain(Executive Officer)in
BoardAlexandra Cantley(Director)inSakae Asanuma(Director)inBriggs Morrison(Executive Officer, Director, Promoter)inIrena Melnikova(Director)in
Board seatTodd Foley· per SEC Form D
Co-investorsLifelinkPfizer Venture InvestmentsBiotechnology Value FundMirae Asset Venture InvestmentPfizer VenturesPolaris Partners+1 more
Reunion Neuroscience is a clinical-stage biopharmaceutical company developing serotonergic psychedelic therapies for mental health conditions such as postpartum depression, adjustment disorder, and generalized anxiety disorder.
BiotechDigital HealthMental HealthMorristown, US
Sahil V. Kirpekar(President and CEO)inGregory Mayes(Executive Officer, Director)Ellen Lubman(Director)Mark Pollack(Executive Officer)inNathan Bryson(Executive Officer)inMark Theeuwes(Executive Officer)in
Board seatAnsbert Gadicke· per SEC Form D
Co-investorsFemHealth VenturesMitsui Global InvestmentPalo Santo VCNovo Holdings
Alesta Therapeutics develops therapies for rare diseases, with research focused on genetic diseases and oncology.
BiotechHealthtech
Ilan Ganot(CEO)inBenit Maru(CMO)Matthias Van Woensel(CSO)in
Co-investorsDroia VenturesFrazier Life SciencesNovartis Venture FundRV Invest GmbHFrazier Healthcare PartnersRTW Investments L.P.+1 more
Protego Bio is a biotech company developing first-in-class therapies for protein misfolding diseases, including its lead candidate PROT-001 for AL amyloidosis, based on research into pharmacological chaperones.
AI & Machine LearningBiotechDeep TechDigital HealthHealthtechSan Diego, US
Brent J. Warner(Executive Officer, Director)inXIN JIANG(President & CEO)inHANK MICHAEL PETRASSI(Executive Officer)JEFFERY KELLY(Director)
BoardTIM LOHOFF(Director)Edward Hurwitz(Director)
Co-investorsDroia VenturesNovartis Venture FundDigitalis VenturesForbionLightspeed Venture PartnersVida Ventures+1 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.